EP Patent

EP4212152A1 — Sacubitril-valsartan dosage regimen for treating heart failure

Assigned to Novartis AG · Expires 2023-07-19 · 3y expired

What this patent protects

The present invention relates to novel pharmaceutical compositions for the treatment of heart failure in a patient.

USPTO Abstract

The present invention relates to novel pharmaceutical compositions for the treatment of heart failure in a patient.

Drugs covered by this patent

Patent Metadata

Patent number: EP4212152A1
Jurisdiction: EP
Classification: —
Expires: 2023-07-19
Drug substance claim: No
Drug product claim: No
Assignee: Novartis AG
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.